

Bipolar Disorders: Therapeutic Options

James W. Jefferson, M.D.

**Clinical Professor of Psychiatry
University of Wisconsin Medical School
Distinguished Senior Scientist
Madison Institute of Medicine**

Part 2: Treatment of Acute Bipolar Depression

Teaching Points

- 1. Treatment algorithms and guidelines rely on both data and expert opinion.**
- 2. Olanzapine/fluoxetine combination is the only FDA-approved product for acute bipolar depression (as of early May 2006).**
- 3. Quetiapine data are quite promising.**
- 4. The role that antidepressants should play or not play in bipolar depression continues to be debated.**

Outline

- I. TIMA Stages of Treatment for Acute Bipolar Depression**
 - A. Lamotrigine – Pros and Cons of Stage I**
 - B. Olanzapine/Fluoxetine Combination – Pros and Cons of Stage II**
 - C. Quetiapine – Pros and Cons of Stage II**
 - D. Antidepressants at Stage IV – Why?**
- II. Antidepressants: Advantages and Disadvantages for Bipolar Depression**

Pre-Lecture Exam

Question 1

- 1. Which Medication is recommended for use in Stage I of TIMA for acute bipolar I depression?**
 - a. Quetiapine**
 - b. Olanzapine/fluoxetine combination**
 - c. Bupropion**
 - d. Lamotrigine**
 - e. Lithium**

Question 2

2. As of early May 2006, which is the only FDA-approved treatment for acute bipolar I depression?
- a. Olanzapine/fluoxetine combination
 - b. Lamotrigine
 - c. Quetiapine
 - d. Bupropion
 - e. Duloxetine

Question 3

- 3. Which of the following was found to be more effective than placebo in two placebo-controlled studies of bipolar I and II depression?**
- a. Lamotrigine**
 - b. Olanzapine**
 - c. Imipramine**
 - d. Quetiapine**
 - e. Aripiprazole**

Question 4

4. Which antidepressant appears to have the highest switch rate when used to treat bipolar depression?
- a. Bupropion
 - b. Sertraline
 - c. Venlafaxine



Bipolar Depression

Acute Bipolar I Depression: Texas Implementation of Medication Algorithms (TIMA)

- **Optimize current mood stabilizer**
- **Antimanic agent if history of severe and/or recent mania**
- **Stage 1 – LTG alone or with antimanic**

Acute Bipolar I Depression: TIMA


- **Stage 1: lamotrigine**
- **Stage 2: quetiapine or olanzapine-fluoxetine combination (OFC)***
- **Stage 3: lithium, lamotrigine, quetiapine or olanzapine-fluoxetine combination**
- **Stage 4: ECT, SSRI, bupropion or venlafaxine**
- **Stage 5: MAOI, TCA, DA agonist, etc.**

*OFC is FDA-approved

Why Lamotrigine in Stage 1?

- **Based on 2 open-label add-on and 2 placebo-controlled monotherapy trials (n=195) (n=25)**
- **“A relatively greater weight of expert consensus”**

Lamotrigine Monotherapy for Bipolar I Depression (7 weeks, n=192)



Lamotrigine Monotherapy in Bipolar I Depression

	50 mg/day		200 mg/day	
	<u>Observed</u>	<u>LOCF</u>	<u>Observed</u>	<u>LOCF</u>
HAM-D ₁₇	S	NS	S	NS
HAM-D ₃₁	NS	NS	NS	NS
MADRS	S	NS	S	S
CGI-S	S	NS	S	S
CGI-I	S	NS	S	S


Lamotrigine for Bipolar I Depression **(multicenter, placebo-controlled)**

- **GW 602 (n=195), GW 603 (n=206),
GW 40910 (n=257)**
- **Lamotrigine did not separate from
placebo on the primary endpoint**

Bipolar Depression: FDA Approved

- **Olanzapine/fluoxetine -- 2003 combination**

Olanzapine/OFC for Bipolar I Depression (2 pooled 8-week studies)



MMRM=Mixed Modal Repeated Measures,
OFC=Olanzapine-Fluoxetine Combination


OFC: The Only FDA-Approved Treatment for Acute BPI Depression

- **Why only TIMA Stage 2?
(long-term tolerability)**
- **How does it compare to LTG?**

Bipolar I Depression: Weight Change Over 8 Weeks

	<u>Kg</u>	<u>≥7%</u>
• Placebo	- 0.5	0.3%
• Olanzapine	+2.6	18.7%
• OFC	+2.8	19.5%

OFC vs. Lamotrigine in Bipolar I Depression



MMRM = mixed model repeated measures analysis of variance; *p<0.05 at individual time point;
Brown EB et al. (2005), NR376. Presented at the 158th Annual Meeting of the APA. Atlanta; May 24

OFC vs. LTG for Bipolar I Depression


(7-week, double-blind, n=410)

- **Results favored OFC (Clinical significance?)**
- **AEs favored LTG: weight, lipids, prolactin, somnolence, dry mouth, tremor**
- **Weight $\geq 7\%$ OLZ: 23%, LTG: 0%**
- **Serious AEs (wide variety): OLZ 1.0%, LTG 5.4%**

Quetiapine for Bipolar I and II Depression (8-week, double-blind, n=539)

- **Dose: 300 or 600 mg/day**
- **Both doses > placebo from week 1 through week 8**

Quetiapine for Bipolar I and II Depression



Quetiapine for Bipolar I and II Depression

Adverse Event Dropouts

Quetiapine 600 mg 26.1%

Quetiapine 300 mg 16.0%

Placebo 8.8%



Bipolar Depression: Quetiapine vs Placebo

Weight Change (8 weeks)

	QTP 600	QTP 300	Placebo
	mg	mg	
Mean change (kg)	1.6	1.0	0.2
>7% increase in weight (%)	9.0	8.5	1.7

Quetiapine for Bipolar I and II Depression

MADRS Total Score



‡p<0.001 vs placebo

ITT, LOCF

Calabrese et al 2005;

In-house data, AstraZeneca Pharmaceutical, LP. December 2005

Antidepressants for Acute Bipolar Depression: TIMA Stage 4


- **Antidepressant + antimanic**
- **Preferred: SSRI, bupropion, venlafaxine**
 - Venlafaxine may have higher switch rate
- **Why only Stage 4 for antidepressants?**
- **Monotherapy in select BD-II**
 - Limited data

Antidepressants in Bipolar Disorder

- **Disadvantages¹**
 - **Poor response**
 - **Manic switches**
 - **Cycle acceleration**
 - **Late response loss**
- **Advantages²**
 - **An exceptional subgroup**

¹Ghaemi SN et al. (2004), Am J Psychiatry 161(1):163-165; ²Altshuler L et al. (2003), Am J Psychiatry 160(7):1252-1262

Antidepressants in Bipolar Disorder: Continue or Discontinue?



Altshuler L et al. (2003), *Am J Psychiatry* 160(7):1252-1262.

Similar findings: Joffe et al. *Acta Psychiatr Scand* 2005;112:105-109


Antidepressants for Bipolar Depression: Systematic Review- 12 Randomized, Controlled Trials

- **Effective short-term (longest was 10 weeks)**
- **Switching not common**
- **Prefer SSRIs, MAOIs over TCAs**
- **To prefer bupropion or paroxetine moves
“beyond the evidence”**

Antidepressant Switch Rate in Bipolar II Disorder (NIMH-CDS)

- **Antidepressant 3.6% switch**
- **No antidepressant 3.5% switch**

STEP 500: *Antidepressants*



Ghaemi SN et al. Presented at: 5th International Conference on Bipolar Disorder; June 2003; Pittsburgh, Pa.

**The Role of Antidepressants or the
Lack Thereof in Bipolar Disorder
Continues to Be Debated**

Post-Lecture Exam

Question 1

1. Which Medication is recommended for use in Stage I of TIMA for acute bipolar I depression?
 - a. Quetiapine
 - b. Olanzapine/fluoxetine combination
 - c. Bupropion
 - d. Lamotrigine
 - e. Lithium

Question 2

2. As of early May 2006, which is the only FDA-approved treatment for acute bipolar I depression?
- a. Olanzapine/fluoxetine combination
 - b. Lamotrigine
 - c. Quetiapine
 - d. Bupropion
 - e. Duloxetine

Question 3

- 3. Which of the following was found to be more effective than placebo in two placebo-controlled studies of bipolar I and II depression?**
- a. Lamotrigine**
 - b. Olanzapine**
 - c. Imipramine**
 - d. Quetiapine**
 - e. Aripiprazole**

Question 4

- 4. Which antidepressant appears to have the highest switch rate when used to treat bipolar depression?**
- a. Bupropion**
 - b. Sertraline**
 - c. Venlafaxine**

Answers to Pre & Post Lecture Exams

1. D

2. A

3. D

4. C